The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

NICE is unable to make a recommendation about the use in the NHS of empagliflozin (Jardiance) for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim did not ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...

Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. There is a simple discount patient ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

Access to hybrid closed loop systems will be through a 5‑year phased roll out in line with NHS England's implementation plan. For enquiries about cost-effective pricing, contact Leigh.Carr@supplychain ...

NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...